Last reviewed · How we verify
kanamycin/metronidazole
Kanamycin is an aminoglycoside antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit, while metronidazole is an antimicrobial agent that kills bacteria by interfering with DNA replication.
Kanamycin is an aminoglycoside antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit, while metronidazole is an antimicrobial agent that kills bacteria by interfering with DNA replication. Used for Bacterial infections, including those caused by anaerobic bacteria and protozoa.
At a glance
| Generic name | kanamycin/metronidazole |
|---|---|
| Sponsor | Japan Multinational Trial Organization |
| Drug class | Aminoglycoside antibiotic, Antimicrobial agent |
| Target | 30S ribosomal subunit, DNA |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
Kanamycin works by binding to the 30S ribosomal subunit, which prevents the initiation complex of peptide formation from being positioned correctly on the mRNA, thereby inhibiting protein synthesis. Metronidazole, on the other hand, is reduced to its active form by bacterial ferredoxin, which then forms a nitroso compound that alkylates DNA, leading to DNA strand breaks and cell death.
Approved indications
- Bacterial infections, including those caused by anaerobic bacteria and protozoa
Common side effects
- Ototoxicity
- Nephrotoxicity
- Gastrointestinal disturbances
Key clinical trials
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Trial of Antibiotic Prophylaxis in Elective Laparoscopic Colorectal Surgery: Oral and Systemic Versus Systemic Antibiotics (PHASE3)
- A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- kanamycin/metronidazole CI brief — competitive landscape report
- kanamycin/metronidazole updates RSS · CI watch RSS
- Japan Multinational Trial Organization portfolio CI